Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review
The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential adverse drug reactions (ADRs) and their predictors...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2022-12-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/340 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849252381092478976 |
|---|---|
| author | A. V. Kryukov A. S. Zhiryakova Yu. V. Shevchuk A. V. Matveev V. I. Vechorko O. V. Averkov S. V. Glagolev I. I. Temirbulatov K. B. Mirzaev N. P. Denisenko Sh. P. Abdullaev D. A. Sychev |
| author_facet | A. V. Kryukov A. S. Zhiryakova Yu. V. Shevchuk A. V. Matveev V. I. Vechorko O. V. Averkov S. V. Glagolev I. I. Temirbulatov K. B. Mirzaev N. P. Denisenko Sh. P. Abdullaev D. A. Sychev |
| author_sort | A. V. Kryukov |
| collection | DOAJ |
| description | The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential adverse drug reactions (ADRs) and their predictors in etiology- and pathogenesis-oriented COVID-19 therapy. According to literature data, the main clinically significant risk factors for COVID-19 patients to develop an ADR are the duration of their hospital stay, combined use of antivirals, polypharmacy, and their history of drug allergies. The most common adverse reactions to antivirals, to virus-neutralising antibodies, and to human anti-COVID-19 immunoglobulin and convalescent plasma are, respectively, gastrointestinal and hepatobiliary disor ders; gastrointestinal disorders, neurological disorders, and allergic reactions; and transfusion reactions (fever, chills, etc.). For pathogenesis-oriented therapy with systemic glucocorticosteroids, the most characteristic ADR is hyperglycaemia. Janus kinase inhibitors and interleukin inhibitors are most often associated with gastrointestinal disorders and hypertransaminasemia; neutropenia is also characteristic of a number of interleukin inhibitors. Haemo static adverse reactions to anticoagulants depend on the patient’s dosing regimen and condition. Drug-drug interactions are a common problem in COVID-19 treatment, with the combination of nirmatrelvir and ritonavir showing the largest number of significant interactions attributed to their pharmacokinetics. Currently, there is data on the role of pharmacogenetic biomarkers in the safety and clinical outcomes of COVID-19 therapy. Thus, to improve the safety of COVID-19 therapy, an integrated approach is needed that will take into account both the clinical, demographic, and pharmacogenetic predictors of ADRs and the risk of drug-drug interactions. |
| format | Article |
| id | doaj-art-5d9ff01bf50b46dfb11a1965a596882f |
| institution | Kabale University |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| publishDate | 2022-12-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj-art-5d9ff01bf50b46dfb11a1965a596882f2025-08-20T03:56:38ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642022-12-0110432634410.30895/2312-7821-2022-10-4-326-344273Safety of Pharmacotherapy in COVID-19 Patients: A Literature ReviewA. V. Kryukov0A. S. Zhiryakova1Yu. V. Shevchuk2A. V. Matveev3V. I. Vechorko4O. V. Averkov5S. V. Glagolev6I. I. Temirbulatov7K. B. Mirzaev8N. P. Denisenko9Sh. P. Abdullaev10D. A. Sychev11Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia); O.M. Filatov City Clinical Hospital No. 15Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia); O.M. Filatov City Clinical Hospital No. 15O.M. Filatov City Clinical Hospital No. 15Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia); O.M. Filatov City Clinical Hospital No. 15Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential adverse drug reactions (ADRs) and their predictors in etiology- and pathogenesis-oriented COVID-19 therapy. According to literature data, the main clinically significant risk factors for COVID-19 patients to develop an ADR are the duration of their hospital stay, combined use of antivirals, polypharmacy, and their history of drug allergies. The most common adverse reactions to antivirals, to virus-neutralising antibodies, and to human anti-COVID-19 immunoglobulin and convalescent plasma are, respectively, gastrointestinal and hepatobiliary disor ders; gastrointestinal disorders, neurological disorders, and allergic reactions; and transfusion reactions (fever, chills, etc.). For pathogenesis-oriented therapy with systemic glucocorticosteroids, the most characteristic ADR is hyperglycaemia. Janus kinase inhibitors and interleukin inhibitors are most often associated with gastrointestinal disorders and hypertransaminasemia; neutropenia is also characteristic of a number of interleukin inhibitors. Haemo static adverse reactions to anticoagulants depend on the patient’s dosing regimen and condition. Drug-drug interactions are a common problem in COVID-19 treatment, with the combination of nirmatrelvir and ritonavir showing the largest number of significant interactions attributed to their pharmacokinetics. Currently, there is data on the role of pharmacogenetic biomarkers in the safety and clinical outcomes of COVID-19 therapy. Thus, to improve the safety of COVID-19 therapy, an integrated approach is needed that will take into account both the clinical, demographic, and pharmacogenetic predictors of ADRs and the risk of drug-drug interactions.https://www.risksafety.ru/jour/article/view/340covid-19adverse drug reactionspharmacovigilancedrug-drug interactionspharmacogeneticsnirmatrelvir+ritonavirinterleukin inhibitorsmonoclonal antibodies |
| spellingShingle | A. V. Kryukov A. S. Zhiryakova Yu. V. Shevchuk A. V. Matveev V. I. Vechorko O. V. Averkov S. V. Glagolev I. I. Temirbulatov K. B. Mirzaev N. P. Denisenko Sh. P. Abdullaev D. A. Sychev Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review Безопасность и риск фармакотерапии covid-19 adverse drug reactions pharmacovigilance drug-drug interactions pharmacogenetics nirmatrelvir+ritonavir interleukin inhibitors monoclonal antibodies |
| title | Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review |
| title_full | Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review |
| title_fullStr | Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review |
| title_full_unstemmed | Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review |
| title_short | Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review |
| title_sort | safety of pharmacotherapy in covid 19 patients a literature review |
| topic | covid-19 adverse drug reactions pharmacovigilance drug-drug interactions pharmacogenetics nirmatrelvir+ritonavir interleukin inhibitors monoclonal antibodies |
| url | https://www.risksafety.ru/jour/article/view/340 |
| work_keys_str_mv | AT avkryukov safetyofpharmacotherapyincovid19patientsaliteraturereview AT aszhiryakova safetyofpharmacotherapyincovid19patientsaliteraturereview AT yuvshevchuk safetyofpharmacotherapyincovid19patientsaliteraturereview AT avmatveev safetyofpharmacotherapyincovid19patientsaliteraturereview AT vivechorko safetyofpharmacotherapyincovid19patientsaliteraturereview AT ovaverkov safetyofpharmacotherapyincovid19patientsaliteraturereview AT svglagolev safetyofpharmacotherapyincovid19patientsaliteraturereview AT iitemirbulatov safetyofpharmacotherapyincovid19patientsaliteraturereview AT kbmirzaev safetyofpharmacotherapyincovid19patientsaliteraturereview AT npdenisenko safetyofpharmacotherapyincovid19patientsaliteraturereview AT shpabdullaev safetyofpharmacotherapyincovid19patientsaliteraturereview AT dasychev safetyofpharmacotherapyincovid19patientsaliteraturereview |